Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May;189(3):e104-e108.
doi: 10.1111/bjh.16515. Epub 2020 Mar 3.

Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Guadalupe Antelo  1 , Abhishek A Mangaonkar  1 , Giacomo Coltro  1 , Ajinkya Buradkar  1 , Terra L Lasho  1 , Christy Finke  1 , Ryan Carr  1 , Moritz Binder  1 , Naseema Gangat  1 , Aref Al-Kali  1 , Michelle A Elliott  1 , Rebecca L King  2 , Matthew Howard  2 , Megan E Melody  3 , William Hogan  1 , Mark R Litzow  1 , Ayalew Tefferi  1 , Martin E Fernandez-Zapico  4 , Rami Komrokji  3 , Mrinal M Patnaik  1
Affiliations
Comment

Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Guadalupe Antelo et al. Br J Haematol. 2020 May.
No abstract available

Keywords: ESA; MDS-RS; MDS/MPN-RS-T; erythropoiesis stimulating agents; myeloid leukaemia; sideroblastic anaemia.

PubMed Disclaimer

Comment on

References

    1. Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M. & Vardiman, J.W. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-2405.
    1. Broseus, J., Florensa, L., Zipperer, E., Schnittger, S., Malcovati, L., Richebourg, S., Lippert, E., Cermak, J., Evans, J., Mounier, M., Raya, J.M., Bailly, F., Gattermann, N., Haferlach, T., Garand, R., Allou, K., Besses, C., Germing, U., Haferlach, C., Travaglino, E., Luno, E., Pinan, M.A., Arenillas, L., Rozman, M., Perez Sirvent, M.L., Favre, B., Guy, J., Alonso, E., Ahwij, N., Jerez, A., Hermouet, S., Maynadie, M., Cazzola, M. & Girodon, F. (2012) Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica, 97, 1036-1041.
    1. Fenaux, P., Santini, V., Spiriti, M.A.A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., Oliva, E.N., Symeonidis, A., Berger, M.H., Gotze, K.S., Potamianou, A., Haralampiev, H., Wapenaar, R., Milionis, I. & Platzbecker, U. (2018) A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia, 32, 2648-2658.
    1. Ferrini, P.R., Grossi, A., Vannucchi, A.M., Barosi, G., Guarnone, R., Piva, N., Musto, P. & Balleari, E. (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology, 103, 1070-1074.
    1. Greenberg, P.L., Sun, Z., Miller, K.B., Bennett, J.M., Tallman, M.S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M.L., Cella, D. & Rowe, J.M. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood, 114, 2393-2400.